Neurodiagnostics Market Overview
The Neurodiagnostics Market is experiencing significant growth, driven by an aging global population, rising prevalence of neurodegenerative diseases, and the rapid integration of AI-augmented diagnostic workflows. The market is undergoing a fundamental transformation, moving from traditional imaging and electrophysiology to advanced, data-integrated platforms that combine AI, blood-based biomarkers, and cloud-based informatics to enable earlier and more precise neurological diagnoses .
As per MRFR analysis, the global Neurodiagnostics Market was valued at USD 9.78 Billion in 2025. The market is projected to grow from USD 10.52 Billion in 2026 to USD 20.36 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.6% during the forecast period 2026–2035.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/8762
Key market players driving innovation and competitiveness in the Neurodiagnostics Market include:
• Siemens Healthineers (DE)
• GE HealthCare (US)
• Philips Healthcare (NL)
• Nihon Kohden (JP)
• Natus Medical (Integra LifeSciences) (US)
• Compumedics (AU)
• Medtronic (US)
• Cadwell Industries (US)
• Masimo Corporation (US)
• BioSignal Group (US)
The market growth is strongly supported by large-scale public investments, such as the U.S. National Institutes of Health’s BRAIN Initiative (over USD 12 billion through 2026) and the European Commission’s Horizon Europe program (EUR 1.8 billion for neuroscience research) . The WHO projects the global population aged 65 and older will double to 1.6 billion by 2050, with Alzheimer’s disease alone affecting an estimated 55 million people worldwide, creating sustained, non-cyclical demand for neurodiagnostic solutions . The commercialization of blood-based biomarkers, particularly p-tau217 assays, is providing a scalable and cost-effective alternative to PET imaging for early Alzheimer’s detection .
The Neurodiagnostics Market segmentation is structured across multiple dimensions. Based on Product Type, it includes Reagents & Consumables (the largest segment), Instruments & Systems, Software & Informatics (fastest-growing), and Gene Therapy Diagnostics . In terms of Technology, the market covers Neuroimaging Technologies (largest), Electrophysiology, Neuroinformatics & AI Analytics (fastest-growing at 12.3% CAGR), and Biomarker & Molecular Diagnostics . The Condition segmentation comprises Neurodegenerative Diseases (largest), Cerebrovascular Disorders, Epilepsy & Seizure Disorders, and Sleep Disorders (fastest-growing) .
Purchase the Complete Report for Strategic Insights and Market Forecasts:
https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=8762
The increasing demand for earlier and more accurate diagnosis, driven by the need to intervene before irreversible neuronal loss, is encouraging the adoption of advanced diagnostic tools. The integration of AI for real-time volumetric analysis, cloud-based platforms for data integration, and portable devices for point-of-care settings is improving diagnostic accuracy and expanding access across care settings .
Recent Developments:
Siemens Healthineers (December 2025): Introduced the MAGNETOM Free: XL, a 0.55T helium-free MRI system designed to enhance interventional radiology workflows and reduce total cost of ownership .
GE HealthCare (January 2025): Announced the expansion of its AIR Recon DL platform, an AI-powered image reconstruction technology, to cover nearly all anatomical imaging .
European Commission (November 2023): The EU AI Act established a risk-based classification framework for AI-enabled medical devices, including neurology software, shaping regulatory pathways .
FDA (2025): Granted clearance to several commercial p-tau217 blood-based biomarker assays, accelerating their transition from research to routine clinical practice .
South Korea (2023): Launched a KRW 490 billion (approx. USD 370 million) “Brain Science Development Strategy” to fund translational diagnostic technologies .
Browse In-depth Market Research Report (Pages, Charts, Tables, Figures):
https://www.marketresearchfuture.com/reports/neurodiagnostics-market-8762
Reasons to Buy the Report:
Provides comprehensive insights into the Neurodiagnostics Market dynamics, trends, and growth potential.
Helps identify emerging opportunities across AI analytics, blood-based biomarkers, and portable neurodiagnostic devices.
Offers detailed segmentation analysis to understand market behavior across product types, technologies, conditions, and end users.
Includes competitive intelligence with strategic profiles of leading neurodiagnostic companies operating globally.
Assists investors and stakeholders in making data-driven decisions supported by market forecasts, competitive analysis, and industry trends.
Future Outlook:
The future of the Neurodiagnostics Market is expected to be shaped by AI-autonomous diagnostic reporting, platform economics, and the convergence of multi-analyte biomarkers for precision neurology. By 2030, AI is expected to play a critical role in triaging and preliminarily analyzing high-volume neuroimaging, allowing specialists to focus on complex cases. The transition toward cloud-based, subscription-based diagnostic platforms is compressing hardware margins but driving robust growth in software and recurring service revenue. By 2035, the neurodiagnostics ecosystem is expected to be a deeply integrated, data-driven pillar of precision medicine, enabling earlier intervention and personalized treatment for neurological disorders .
➤➤Explore MRFR’s Related Ongoing Coverage In Healthcare Domain:
